AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
contas de clientes
A FxPro oferece aos clientes seus serviços de negociação on-line desde 1999, atendendo atualmente 173 países no mundo todo.
Prémios
A FxPro recebe constantemente reconhecimento na indústria, tendo vencido mais de 145 prêmios internacionais até o momento pela qualidade de seus serviços.
atendimento ao Cliente
Nossa equipe exclusiva de atendimento multilíngue trabalha 24 horas por dia para oferecer um nível excepcional de suporte.
regulamentos da indústria
A FxPro opera sob rigorosa supervisão regulatória em diversas jurisdições, incluindo autorização da FCA no Reino Unido — um dos reguladores financeiros mais confiáveis do mundo.
